Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8]naphthyridine derivatives on human stimulated PMN and endothelial cells: An in vitro study

被引：23

作者：

Dianzani C. ^{[1
]}

Collino M. ^{[1
]}

Gallicchio M. ^{[1
]}

Di Braccio M. ^{[2
]}

Roma G. ^{[2
]}

Fantozzi R. ^{[1
]}

机构：

[1] Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, 10125 Torino

[2] Department of Pharmaceutical Sciences, University of Genoa, 16132 Genoa

来源：

Journal of Inflammation | / 3卷 / 1期

关键词：

Platelet Activate Factor; Phorbol Myristate Acetate; Human Umbilical Vascular Endothelial Cell; PGI2 Production; Fluorescein Diacetate;

D O I：

10.1186/1476-9255-3-4

中图分类号：

学科分类号：

摘要：

Background: [1,2,4] triazolo [4, 3-a][1,8]naphthyridine derivatives (including NF161 and NF177) were tested for anti-inflammatory, analgesic and antipyretic properties and for their effects on spontaneous locomotor activity in mice and acute gastrolesivity in rats. Both NF161 and NF177 appeared to be anti-inflammatory and analgesic agents without toxic effects or acute gastrolesivity, but NF161 showed stronger anti-inflammatory activity, whereas NF177 was more active as analgesic. Methods: An EIA kit was used to investigate the ability of NF161 and NF177 to affect prostaglandin E2 (PGE2) and prostacyclin (PGI2) production by human umbilical vascular endothelial cells (HUVEC). The compounds' effects on the production of reactive oxygen species (ROS) by human polymorphonuclear cells (PMNs) were studied in an in vitro cell model, evaluating inhibition of superoxide anion (O2-.) production induced by N-formylmethionyl-leucyl-phenylalanine (FMLP). Their effects on PMN adhesion to HUVEC were also investigated; they were incubated with PMNs and endothelial cells (EC) and challenged by stimuli including Platelet Activating Factor (PAF), FMLP, Phorbol Myristate Acetate (PMA), Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β). Adhesion was quantitated by computerized micro-imaging fluorescence analysis. Results: Neither compounds modified PGE2 or PGI2 production induced by IL-1α. O2-. production and myeloperoxidase release from PMNs stimulated by FMLP was inhibited in a dose- but not time-dependent manner by both [1,8]naphthyridine derivatives, NF161 being statistically more active than NF177 (P < 0.01). The compounds inhibited adhesion evoked by the pro-inflammatory stimuli PAF, FMLP, TNF-α and IL-1β in a concentration-dependent manner in the 10-6-10-4M range, being more active when PAF was used as stimulus and inactive when cells were challenged by PMA. Both compounds acted both on PMN and HUVEC. Conclusion: Considering the interesting anti-inflammatory effects of these compounds in in vivo models and the absence of acute gastrolesivity, the study improved knowledge of anti-inflammatory properties of NF161 and NF177, also demonstrating their potential in vitro, through inhibition of O2-. production, myeloperoxidase release and PMN adhesion to HUVEC. Negative results on PG production suggest a cyclooxygenase (COX)-independent mechanism. © 2006Dianzani et al; licensee BioMed Central Ltd.

引用

共 46 条

[1]

Vane J.R., Bakhle Y.S., Botting R.M., Cyclooxygenases 1 and 2, Annu Rev Pharmacol Toxicol, 38, pp. 97-120, (1998)

[2]

Caughey G.E., Cleland L.G., Penglis P.S., Gamble J.R., James M.J., Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2, J Immunol, 167, pp. 2831-2838, (2001)

[3]

Eligini S., Habib A., Lebret M., Creminon C., Levy-Too S., Maclouf J., Induction of cyclo-oxygenase-2 in human endothelial cells by SIN-1 in the absence of prostaglandin production, Br J Pharmacol, 133, pp. 1163-1171, (2001)

[4]

Bouzard D., Di Cesare P., Essiz M., Jacquet J.P., Ledoussal B., Remuzon P., Kessler R.E., Fung-Tomc J., Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acids, J Med Chem, 35, pp. 518-525, (1992)

[5]

Ferrarini P.L., Manera C., Mori C., Badawneh M., Saccomanni G., Synthesis and evaluation of antimycobacterial activity of 4-phenyl-1, 8-naphthyridine derivatives, Farmaco, 53, pp. 741-746, (1998)

[6]

Zhang S.X., Bastow K.F., Tachibana Y., Kuo S.C., Hamel E., Mauger A., Narayanan V.L., Lee K.H., Antitumor agents 196 Substituted 2-thienyl-1, 8-naphthyridin-4-ones: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization, J Med Chem, 42, pp. 4081-4087, (1999)

[7]

Kuroda T., Suzuki F., Tamura T., Ohmori K., Hosoe H., A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1H)-oxo-1-phenyl-1, 8-naphthyridine-3-carboxamides, J Med Chem, 35, pp. 1130-1136, (1992)

[8]

Ferrarini P.L., Badawneh M., Franconi F., Manera C., Miceli M., Mori C., Saccomanni G., Synthesis and antiplatelet activity of some 2, 7-di(N-cycloamino)-3-phenyl-1, 8-naphthyridine derivatives, Farmaco, 56, pp. 311-318, (2001)

[9]

Santilli A.A., Scotese A.C., Bauer R.F., Bell S.C., 2-Oxo-1, 8-naphthyridine-3-carboxylic acid derivatives with potent gastric antisecretory properties, J Med Chem, 30, pp. 2270-2277, (1987)

[10]

Kuo S.C., Tsai S.Y., Li H.T., Wu C.H., Ishii K., Nakamura H., Studies on heterocyclic compounds IX Synthesis and antiallergic activity of furo [2, 3-b] [1, 8]naphthyridine-3, 4(2H, 9H)-diones and 4H-furo[2, 3-d]pyrido[1, 2-alpha]-pyrimidine-3, 4(2H)-diones, Chem Pharm Bul, 36, pp. 4403-4407, (1988)

← 1 2 3 4 5 →